-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, KqMWnsDO9BRMLr6nYaVBky7s/CjuF5MeDjT1XNogXcBFnFv1gxyFJF2NsSZWVGLf tA08Skbn3tDbV9AXQrT9hw== 0001238948-07-000006.txt : 20070702 0001238948-07-000006.hdr.sgml : 20070702 20070702182510 ACCESSION NUMBER: 0001238948-07-000006 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20070629 FILED AS OF DATE: 20070702 DATE AS OF CHANGE: 20070702 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIOSITE INC CENTRAL INDEX KEY: 0000834306 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 330288606 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 11030 ROSELLE ST CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 6194554808 MAIL ADDRESS: STREET 1: 11030 ROSELLE ST CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: BIOSITE DIAGNOSTICS INC DATE OF NAME CHANGE: 19960710 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: WOLLAEGER TIMOTHY J CENTRAL INDEX KEY: 0001238948 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-21873 FILM NUMBER: 07956847 BUSINESS ADDRESS: STREET 1: C/O BIOSITE INC STREET 2: 11030 ROSELLE STREET CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8584554808 4 1 edgardoc.xml PRIMARY DOCUMENT X0202 4 2007-06-29 1 0000834306 BIOSITE INC BSTE 0001238948 WOLLAEGER TIMOTHY J BIOSITE INCORPORATED 9975 SUMMERS RIDGE ROAD SAN DIEGO CA 92121 1 0 0 0 Non-Qualified Stock Option (right to buy) 44.18 2007-06-29 4 D 0 1253 0 D 2014-06-18 Common Stock 1253 0 D Non-Qualified Stock Option (right to buy) 45.02 2007-06-29 4 D 0 4062 0 D 2016-11-01 Common Stock 4062 0 D Non-Qualified Stock Option (right to buy) 53.38 2007-06-29 4 D 0 2500 0 D 2015-06-17 Common Stock 2500 0 D This option, which provided for daily vesting over a four-year period commencing on the date of grant, was assumed by Inverness Medical Innovations ("Inverness") pursuant to a merger agreement between the Issuer and Inverness and replaced with an option to purchase 2,244 shares of Inverness common stock for $24.66 per share. This option, which provided for vesting in sixteen equal quarterly installments over a four-year period commencing on the date of grant was assumed by Inverness Medical Innovations ("Inverness") pursuant to a merger agreement between the Issuer and Inverness and replaced with an option to purchase 7,277 shares of Inverness common stock for $25.13 per share. This option, which provided for vesting in sixteen equal quarterly installments over a four-year period commencing on the date of grant was assumed by Inverness Medical Innovations ("Inverness") pursuant to a merger agreement between the Issuer and Inverness and replaced with an option to purchase 4,478 shares of Inverness common stock for $29.80 per share. By: Robyn Shutak For: Timothy Wollaeger 2007-07-02 -----END PRIVACY-ENHANCED MESSAGE-----